Advertisement

Complications of Myocardial Infarction and Postinfarction Care

Chapter
  • 712 Downloads
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Knowledge of the probable outcome after myocardial infarction (MI) is important in formulating an appropriate plan of management, as with ST elevation MI versus non-ST elevation MI (non-Q-wave MI). The following information on risk stratification is relevant to decision making.

Keywords

Cardiogenic Shock Severe Heart Failure Left Ventricular Aneurysm Ventricular Septal Rupture Papillary Muscle Rupture 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

  1. 1.
    AIRE: The acute infarction ramipril efficacy (AIRE) study investigators. Effect orramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821.Google Scholar
  2. 2.
    Ambrosioni E, Borghi C, Magnani B. For the survival of myocardial infarction longterm evaluation (SMILE) study investigators. N Engl J Med 1995;332:80.PubMedCrossRefGoogle Scholar
  3. 3.
    Aronow WS, Ahn C, Mercando AD, et al. Circadian variation of sudden cardiac death or fatal MI is abolished by propranolol in patients with heart disease and complex ventricular arrhythmias. Am J Cardiol 1994;74:819.PubMedCrossRefGoogle Scholar
  4. 4.
    Becker RC, Charlesworth A, Wilcox RG, et al. Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the late assessment of thrombolytic efficacy (late) study. J Am Coll Cardiol 1995;25:1063.PubMedCrossRefGoogle Scholar
  5. 5.
    BHAT: Peters RW, Muller JE, Goldstein S, et al. For the BHAT study group. Propranolol and the morning increase in the frequency of sudden cardiac deaths. Am J Cardiol 1989;63:1518.PubMedCrossRefGoogle Scholar
  6. 6.
    Birnbaum Y, Fischbein MC, Blanche C, et al. Ventricular septal rupture after myocardial infarction. N Engl J Med 2002;347:1426–1431.PubMedCrossRefGoogle Scholar
  7. 7.
    Brand DA, Newcomer LN, Freiburger A, et al. Cardiologists’ practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol 1995;26:1432.PubMedCrossRefGoogle Scholar
  8. 8.
    Burkart F, Pfisterer, Kiowski W, et al. Effects of antiarrhythmic therapy on mortality in basel antiarrhythmic study of infarct survival (BASIS). J Am Coll Cardiol 1990;16:1711.PubMedGoogle Scholar
  9. 9.
    Cannon CP, Braunwald E, McCabe CH. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [PROVE IT—TIMI 22 trial]. N Engl J Med 2004;350:1495–1504.PubMedCrossRefGoogle Scholar
  10. 10.
    CAPRICORN Investigators. The effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction. The CAPRICORN randomized trial. Lancet 2001;237:1385–1390.Google Scholar
  11. 11.
    CHARM: Granger CB, McMurray JJV, Yusuf S, et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin converting enzyme inhibitors; the CHARM alternative trial. Lancet 2003;362:772–776.PubMedCrossRefGoogle Scholar
  12. 12.
    COPERNICUS: carvedilol Prospective randomized cumulative survival study group effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–1658.Google Scholar
  13. 13.
    The Danish study group on verapamil in myocardial infarction. Secondary prevention with verapamil after myocardial infarction. Am J Cardiol 1990;66:331.Google Scholar
  14. 14.
    Granger CB, McMurray JJV, Yusuf S, et al. for the CHARM Investigators and Committees. Effects of cardesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin converting enzyme inhibitors; the CHARM-alternative trial. Lancet 2003;362:772–776.PubMedCrossRefGoogle Scholar
  15. 15.
    Gruppo italiano per lo studio della sopravvivenza nell’infarto miocardico. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the Gissi-3 trial. J Am Coll Cardiol 1996;27:337.CrossRefGoogle Scholar
  16. 16.
    Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001;285:190–192.PubMedCrossRefGoogle Scholar
  17. 17.
    HOPE: The heart outcomes prevention evaluation (HOPE) study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 2000;342:145.CrossRefGoogle Scholar
  18. 18.
    Jensen GVH, Torp-Pedersen C, Kober L, et al. Prognosis of late versus early ventricular fibrillation in acute myocardial infarction. Am J Cardiol 1990;66:10.PubMedCrossRefGoogle Scholar
  19. 19.
    Lane D, Carroll D, Lip GYH. Anxiety, depression, and prognosis after myocardial infarction: Is there acausal association? J Am Coll Cardiol 2003;42:1808–1810.PubMedCrossRefGoogle Scholar
  20. 20.
    Macmahon S, Collins R, Peto R, et al. Effects of prophylactic lidocaine in suspected acute myocardial infarction. JAMA 1988;260:1910.PubMedCrossRefGoogle Scholar
  21. 21.
    McMurray JJV, Pfeffer MA, Swedberg K, et al. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation 2004;110:3281–3288.PubMedCrossRefGoogle Scholar
  22. 22.
    Oliva PB, Hammili SC, Edwards WD. Cardiac rupture, a clinically predictable complication of acute myocardial infarction: report of 70 cases with clinical pathologic correlations. J Am Coll Cardiol 1993;22:720.PubMedCrossRefGoogle Scholar
  23. 23.
    Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Circulation 1990;81:1161.PubMedGoogle Scholar
  24. 24.
    Pitt B. ACE inhibitors for patients with vascular disease without left ventricular dysfunction—may they rest in PEACE? N Engl J Med 2004;351:2115–2117.PubMedCrossRefGoogle Scholar
  25. 25.
    Pitt B. A new HOPE for aldosterone blockade? Circulation 2004;110:1714–1716.PubMedCrossRefGoogle Scholar
  26. 26.
    Pitt B. Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation 2003;108:1790–1794.PubMedCrossRefGoogle Scholar
  27. 27.
    Pitt B. Aldosterone blockade in patients with acute myocardial infarction. Circulation 2003;107:2525–2527.PubMedCrossRefGoogle Scholar
  28. 28.
    Pitt B, Remme W, Zannad F, et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigatores (EPHESUS). Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl Med 2003;348:1309–1321.CrossRefGoogle Scholar
  29. 29.
    Pohjola-Sintonen S, Muller JE, Stone PH, et al. Milis study group: ventricular septal and freewall rupture complicating acute myocardial infarction: experience in the multicenter investigation of limitation of infarct size. Am Heart J 1989;117:809.PubMedCrossRefGoogle Scholar
  30. 30.
    Szmitko PE, Verma S. Red wine and your heart. Circulation 2005;111:e10–e11.PubMedCrossRefGoogle Scholar
  31. 31.
    Topol EJ. Arthritis medicines and cardiovascular events—“House of Coxibs.” JAMA 2005;293:366–368.PubMedCrossRefGoogle Scholar
  32. 32.
    Valiant: Pfeffer MA, McMurray JJ, Velazquez EJ, et al. for the valsartan in acute myocardial infarction trial investigators. Valsartan captopril or both in myocardial infarction complicated by heart failure left ventricular dysfunction or both. N Eng J Med 2003;349:1893–1906.CrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Personalised recommendations